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Recent studies demonstrated that activation of the GABAB receptor, either by means of
orthosteric agonists or positive allosteric modulators (PAMs), inhibited different nicotine-
related behaviors, including intravenous self-administration and conditioned place prefer-
ence, in rodents. The present study investigated whether the anti -nicotine effects of the
GABAB receptor agonist, baclofen, and GABAB PAMs, CGP7930, and GS39783, extend
to nicotine stimulant effects. To this end, CD1 mice were initially treated with baclofen
(0, 1.25, and 2.5mg/kg, i.p.), CGP7930 (0, 25, and 50mg/kg, i.g.), or GS39783 (0, 25, and
50mg/kg, i.g.), then treated with nicotine (0 and 0.05mg/kg, s.c.), and ﬁnally exposed to
an automated apparatus for recording of locomotor activity. Pretreatment with doses of
baclofen, CGP7930, or GS39783 that did not alter locomotor activity when given with nico-
tine vehicle fully prevented hyperlocomotion induced by 0.05mg/kg nicotine. These data
extend to nicotine stimulant effects the capacity of baclofen and GABAB PAMs to block
the reinforcing, motivational, and rewarding properties of nicotine. These data strengthen
the hypothesis that activation of the GABAB receptor may represent a potentially useful,
anti -smoking therapeutic strategy.
Keywords: GABAB receptor, baclofen, positive allosteric modulation of the GABAB receptor, CGP7930, GS39783,
nicotine-induced hyperlocomotion, mouse
INTRODUCTION
Multiple experimental and clinical data suggest that drugs activat-
ing the GABAB receptor constitute a new class of pharmacological
agents with potential anti-addictive properties: treatment with
both orthosteric GABAB receptor agonists and positive allosteric
modulators (PAMs) of the GABAB receptor has indeed been
reported to suppress several behaviors related to alcohol, cocaine,
d-amphetamine, heroin, γ-hydroxybutyric acid, and nicotine in
rodents as well as alcohol, cocaine, and nicotine taking in humans
(see Addolorato and Leggio, 2010; Tyacke et al., 2010; Vlachou
and Markou, 2010). Focusing on nicotine, the GABAB receptor
agonists, baclofen and CGP44532, have repeatedly been reported
to block (a) intravenous self-administration of nicotine (Corri-
gall et al., 2000, 2001; Fattore et al., 2002; Paterson et al., 2004,
2005b), (b) cue-induced reinstatement of nicotine-seeking behav-
ior (Paterson et al., 2005b; Fattore et al., 2009), (c) conditioned
place preference to nicotine (Le Foll et al., 2008), and (d) nicotine-
induced lowering of threshold for intracranial self-stimulation
(Paterson et al., 2005a) in rats andmice. At clinical level, treatment
with baclofen reduced (a) the number of cigarets smoked per day
in a double-blind placebo-controlled study (Franklin et al., 2009)
and (b) cigaret enjoyment and palatability in a human laboratory
study (Cousins et al., 2001).
More recently, similar data have been collected with GABAB
PAMs: administration of CGP7930, GS39783, and BHF177 –
three of the few, presently available, in vivo effective GABAB
PAMs – suppressed indeed (a) intravenous self-administration of
nicotine (Paterson et al., 2008; Vlachou et al., 2011), (b) cue-
induced reinstatement of nicotine-seeking behavior (Vlachou
et al., 2011), (c) development of conditioned place preference to
nicotine (Mombereau et al., 2007), and (d) nicotine-induced low-
ering of threshold for intracranial self-stimulation (Paterson et al.,
2008), in rats. These data, suggesting that the anti-nicotine prop-
erties of baclofen extend to GABAB PAMs, are theoretically of
therapeutic interest as GABAB PAMs are expected to display fewer
undesirable side-effects compared to GABAB receptor agonists
(see Vlachou and Markou, 2010).
Low-to-moderate doses of nicotine have been repeatedly
reported to stimulate locomotor activity in rats and mice (e.g.,
Jerlhag and Engel, 2011; for review, see Hendry and Rosecrans,
1982). Locomotor hyperactivity has been proposed to repre-
sent an index of the stimulatory and euphorigenic-like effects of
drugs of abuse (see Wise and Bozarth, 1987; Phillips and Shen,
1996) and constitutes – together with self-administration, induc-
tion of conditioned place preference, facilitation of intracranial
self-stimulation, and elicitation of discriminative stimulus effects
similar to those of other addictive drugs – the behavioral crite-
ria deﬁning the addiction potential of a psychoactive drug. The
present study was designed to extend to nicotine-stimulated loco-
motor activity the suppressing effects of baclofen and GABAB
PAMs on several nicotine-related behaviors and address the ques-
tion as to whether drugs activating the GABAB receptor may
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suppress nicotine stimulant effects, beside nicotine reinforcing,
motivational, and rewarding properties (see above for references).
To this end, mice were acutely pretreated with per se ineffective
doses of baclofen, CGP7930, or GS39783, and then acutely treated
with a stimulating dose of nicotine; immediately after nicotine
administration,mice were exposed to an automated apparatus for
recording of locomotor activity.
MATERIALS AND METHODS
The experimental procedures employed in the present study were
in accordance with the European Communities Council Directive
(86/609/EEC) and the subsequent Italian Law on the Protection
of animals used for experimental and other scientiﬁc reasons.
ANIMALS
A total of n= 288 male CD1 mice (Charles River, Calco, Italy),
weighing 35–40 g, were used. Mice were housed 10 per cage in
standard plastic cages with wood chip bedding. The animal facil-
itywas under a 12:12-h light–dark cycle (lights on at 7:00 a.m.), at a
constant temperature of 22± 2˚C and relative humidity of approx-
imately 60%. Tap water and standard rodent chow (Mucedola,
Settimo Milanese, Italy) were always available in the homecage.
EXPERIMENTAL PROCEDURE
Locomotor activity was measured in Plexiglas test cages
[480 hmm× 480 hmm× 400 hmm] by a computer-operated,
photocell-equipped apparatus (Motil, TSE, Bad Homburg, Ger-
many). Test cages were located in a sound-proof room, adjacent
to the housing room. Locomotor activity sessions were conducted
during the ﬁrst 6 h of the light phase of the light/dark cycle.
Three independent experiments were conducted, each one
testing separately baclofen, CGP7930, or GS39783. In each experi-
ment,mice were divided into six independent groups of n= 14–18
mice each. Mice were fasted 1 h before administration of baclofen,
CGP7930, or GS39783. Locomotor activity sessions were con-
ducted as follows: mice were (a) treated with baclofen, CGP7930,
orGS39783, (b) exposed to themotility cage for 60min (this initial,
adaptation phase was expected to provide relatively low baseline
levels of spontaneous locomotor activity at the time of nicotine
treatment, i.e., a desirable condition to amplify the stimulant effect
of nicotine), (c) removed and treated with nicotine, and (d) re-
exposed to the motility cage for a ﬁnal 20-min period. Locomotor
activity counts over the period preceding nicotine administration
provided baseline levels.Mice from each homecagewere randomly
allocated to the different experimental groups and tested simulta-
neously. Mice were exposed to the test cage only once. At the end
of each trial, the test cage was cleaned thoroughly.
Baclofen (Novartis, Basel, Switzerland) was dissolved in saline
and administered at the doses of 0, 1.25, and 2.5mg/kg. Baclofen
was administered intraperitoneally as this route of administra-
tion has consistently been used in most of the studies testing its
anti-nicotine effects (e.g., Paterson et al., 2004; Le Foll et al., 2008;
Fattore et al., 2009). CGP7930 (synthesized by WF) was dissolved
in a 4:1:15 mixture containing Cremophor EL, 1,2-propanediol,
and distilled water and administered at the doses of 0, 25, and
50mg/kg. GS39783 (synthesized by CM, SP, and FC) was sus-
pended in distilled water with a few drops of Tween 80 and
administered at the doses of 0, 25, and 50mg/kg. CGP7930 and
GS39783were administered intragastrically as this route of admin-
istration has consistently been used in most of the studies testing
their anti-nicotine effects (e.g., Mombereau et al., 2007; Paterson
et al., 2008; Vlachou et al., 2011). Nicotine (tartrate salt; Sigma,
Milan, Italy) was dissolved in saline and administered subcuta-
neously at the doses of 0 and 0.05mg/kg (expressed as free base).
Nicotine dose, route of administration, and time of locomotor
activity recording after nicotine injection were chosen on the basis
of preliminary results and literature data (e.g., Freeman et al., 1987;
Kita et al., 1988; Kim and Kim, 1999) as the most appropriate to
detect nicotine-induced hyperactivity in mice. Injection volume
was 12.5ml/kg for all drugs.
STATISTICAL ANALYSIS
The measured variable was the total number of counts (photocell
breaks) recorded automatically by the apparatus over the 20-min
session. Data from each experiment were statistically analyzed by
a two-way (dose of the GABAB ligand; dose of nicotine) analy-
sis of variance (ANOVA), followed by the Newman–Keuls test for
post hoc comparisons.
RESULTS
In all three experiments (testing baclofen,CGP7930, andGS39783,
respectively), baseline levels – i.e., the locomotor activity occur-
ring during the 60-min initial period of “adaptation” to the test
cage – did not differ among mouse groups (data not shown).
In the experiment testing baclofen (Figure 1),ANOVA revealed
a signiﬁcant effect of baclofen dose [F(2,78)= 6.21,P< 0.005], no
effect of nicotine dose [F(1,78)= 0.67,P> 0.05], and a signiﬁcant
interaction [F(2,78)= 7.67, P< 0.001]. Nicotine administration
FIGURE 1 | Prevention of nicotine-induced hyperlocomotion by
baclofen in male CD1 mice. Mice were initially treated with baclofen (i.p.);
60min later, mice were treated with nicotine (tartrate salt). Locomotor
activity recording started immediately after nicotine administration and
lasted for 20 consecutive min. Data are expressed as mean±SEM of the
total number of counts (photocell breaks) recorded automatically by the
apparatus in n=14 mice. *, P<0.01 and §, P<0.0005 (Newman–Keuls
test).
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resulted in a marked stimulation of locomotor activity: at the end
of the 20-min session, the number of counts in “0mg/kg baclofen
plus 0.05mg/kg nicotine”-treated mice was approximately 80%
higher than that recorded in control mice (“0mg/kg baclofen
plus 0mg/kg nicotine”). When given with nicotine vehicle, no
dose of baclofen altered locomotor activity (“1.25mg/kg baclofen
plus 0mg/kg nicotine”and“2.5mg/kg baclofen plus 0mg/kg nico-
tine”mouse groups). Conversely, pretreatment with both doses of
baclofen resulted in complete blockade of the locomotor stimulant
effect of nicotine (“1.25mg/kg baclofen plus 0.05mg/kg nico-
tine” and “2.5mg/kg baclofen plus 0.05mg/kg nicotine” mouse
groups). Combination of the highest dose of baclofen and nico-
tine (“2.5mg/kg baclofen plus 0.05mg/kg nicotine”mouse group)
resulted in a tendency toward a reduction in locomotor activ-
ity compared to control mice (“0mg/kg baclofen plus 0mg/kg
nicotine”).
In the experiment testing CGP7930 (Figure 2), ANOVA
revealed a signiﬁcant effect of nicotine dose [F(1,90)= 8.00,
P< 0.01], no effect of CGP7930 dose [F(2,90)= 2.55, P> 0.05],
and an almost signiﬁcant interaction [F(2,90)= 2.95, P= 0.058].
Nicotine administration resulted in a marked stimulation of loco-
motor activity: at the end of the 20-min session, the number of
counts in “0mg/kg CGP7930 plus 0.05mg/kg nicotine”-treated
mice was approximately 100% higher than that recorded in con-
trolmice (“0mg/kgCGP7930 plus 0mg/kg nicotine”).When given
withnicotine vehicle,nodose of CGP7930 altered locomotor activ-
ity (“25mg/kg CGP7930 plus 0mg/kg nicotine” and “50mg/kg
CGP7930 plus 0mg/kg nicotine”mouse groups). Conversely, pre-
treatment with both doses of CGP7930 resulted in complete
blockade of the locomotor stimulant effect of nicotine (“25mg/kg
CGP7930 plus 0.05mg/kg nicotine” and “50mg/kg CGP7930 plus
0.05mg/kg nicotine”mouse groups).
In the experiment testingGS39783 (Figure 3),ANOVArevealed
a signiﬁcant effect of nicotine dose [F(1,102)= 8.93, P< 0.005],
no effect of GS39783 dose [F(2,102)= 1.09, P> 0.05], and a sig-
niﬁcant interaction [F(2,102)= 3.38, P< 0.05]. Nicotine admin-
istration resulted in a marked stimulation of locomotor activ-
ity: at the end of the 20-min session, the number of counts in
“0mg/kg GS39783 plus 0.05mg/kg nicotine”-treated mice was
approximately 110% higher than that recorded in control mice
(“0mg/kg GS39783 plus 0mg/kg nicotine”). When given with
nicotine vehicle, no dose of GS39783 altered locomotor activ-
ity (“25mg/kg GS39783 plus 0mg/kg nicotine” and “50mg/kg
GS39783 plus 0mg/kg nicotine” mouse groups). Conversely, pre-
treatment with 50mg/kg GS39783 resulted in a complete block-
ade of the locomotor stimulant effect of nicotine (“50mg/kg
GS39783 plus 0.05mg/kg nicotine” mouse group); pretreatment
with 25mg/kg GS39783 produced a tendency toward a reduction
of the locomotor stimulant effect of nicotine (“25mg/kg GS39783
plus 0.05mg/kg nicotine”mouse group).
DISCUSSION
The results of the present study demonstrate the capacity of the
orthosteric GABAB receptor agonist, baclofen, and the GABAB
PAMs, CGP7930, and GS39783, to inhibit nicotine stimulant
effects. Indeed, treatment with non-sedative doses of baclofen,
CGP7930, or GS39783 completely prevented nicotine-induced
FIGURE 2 | Prevention of nicotine-induced hyperlocomotion by
CGP7930 in male CD1 mice. Mice were initially treated with CGP7930
(i.g.); 60min later, mice were treated with nicotine (tartrate salt). Locomotor
activity recording started immediately after nicotine administration and
lasted for 20 consecutive min. Data are expressed as mean±SEM of the
total number of counts (photocell breaks) recorded automatically by the
apparatus in n=16–18 mice. +, P<0.05 and *, P<0.01 (Newman–Keuls
test).
FIGURE 3 | Prevention of nicotine-induced hyperlocomotion by
GS39783 in male CD1 mice. Mice were initially treated with GS39783
(i.g.); 60min later, mice were treated with nicotine (tartrate salt). Locomotor
activity recording started immediately after nicotine administration and
lasted for 20 consecutive min. Data are expressed as mean±SEM of the
total number of counts (photocell breaks) recorded automatically by the
apparatus in n=18 mice. +, P<0.05 and *, P<0.01 (Newman–Keuls test).
hyperlocomotion in mice. These data extend to the stimulant
effects of nicotine the capacity of GABAB receptor agonists and
GABAB PAMs to inhibit nicotine reinforcing, motivational, and
rewarding properties in rodents. Multiple lines of experimen-
tal evidence have indeed demonstrated that treatment with the
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GABAB receptor agonists, baclofen and CGP44532, or the GABAB
PAMs, CGP7930, GS39783, and BHF177, suppressed (a) intra-
venous self-administration of nicotine, (b) cue-induced reinstate-
ment of nicotine-seeking behavior, (c) conditioned place prefer-
ence to nicotine, and (d) nicotine-induced lowering of threshold
for intracranial self-stimulation in rats andmice (see the Introduc-
tion for references). Notably, data on baclofen has been extended
to humans: treatment with baclofen reduced the daily number of
smoked cigarets (Franklin et al., 2009) as well as cigaret enjoyment
and palatability (Cousins et al., 2001).
Together, the results of the present study suggest that activation
of the GABAB receptor – either by means of an orthosteric ago-
nist or PAMs – blocks several psychopharmacological effects of
nicotine; these multiple lines of experimental evidence also sug-
gest that the GABAB receptor can be considered a promising target
for development of potentially useful anti-smoking medications.
GABAB PAMs are devoid of substantial intrinsic agonistic activity
at the GABAB receptor: they do not perturb receptor signaling on
their own, but potentiate the effect of GABA only where and when
it is endogenously released (see Froestl, 2010; Urwyler, 2011). By
targeting only endogenously activated receptors, rather than their
whole population,PAMs are expected to produce fewer side-effects
and lower tolerance. Accordingly, their anti-addictive and anxi-
olytic effects occur at doses considerably lower than those required
to produce hypolocomotion and sedation (e.g., Cryan et al., 2004;
Maccioni et al., 2008; see Vlachou and Markou, 2010). The high
therapeutic index of GABAB PAMs theoreticallymakes these drugs
clearly preferable over baclofen and other GABAB receptor ago-
nists, the non-selective suppressant effects of which occur at doses
relatively close to those producing the desirable pharmacologi-
cal effects. Studies are now needed to assess whether the favorable
“safety”proﬁle of GABAB PAMs observed in rodentsmay be trans-
posed to humans; should this be the case, GABAB PAMs would
represent a class of improved therapeutic compounds for pharma-
cological intervention on GABA neurotransmission (including, to
stay focused on the issue of the present study, nicotine addiction).
The data collected in the present study are also consonant
with several ﬁndings indicating that pretreatment with baclofen or
GS39783 suppressed hyperlocomotion induced in rats andmice by
acute injection of other drugs of abuse, including alcohol (Quin-
tanilla et al., 2008; Holstein et al., 2009), cocaine (Kalivas et al.,
1990; Lhuillier et al., 2007), morphine (Woo et al., 2001; Leite-
Morris et al., 2002), and d-amphetamine (Kalivas et al., 1990;
Phillis et al., 2001). Together, these data suggest that activation
of the GABAB receptor may suppress the stimulant, euphorigenic-
like properties of different drugs of abuse, underlining – once
more – the therapeutic, anti-addictive potential of baclofen and
GABAB PAMs.
It is widely thought that the addictive properties of nicotine
are based on its capacity to alter the activity of the mesolimbic
dopamine (DA) neurons and to enhance DA release in termi-
nal areas (e.g., Jerlhag and Engel, 2011; for review, see Di Chiara,
2000; Mansvelder and McGehee, 2002; Laviolette and van der
Kooy, 2004). These neurons originate in the ventral tegmental area
(VTA) and project their axons to forebrain regions, including the
nucleus accumbens (NAc). GABAB receptors are abundant in the
VTA,where they are located both on cellular bodies of DA neurons
and presynaptic terminals of glutamate neurons (Bowery et al.,
1987); their activation inhibits the activity of mesolimbic DA neu-
rons andDA release in theNAc (e.g.,Yoshida et al., 1994;Westerink
et al., 1996; Xi and Stein, 1998). These GABAB receptors located
in the VTA are the likely site of action of the inhibitory effects
of GABAB receptor ligands on nicotine reinforcing, motivational,
rewarding, and stimulant properties: baclofen and GABAB PAMs
would potentiate the GABAergic inhibitory tone in the VTA, sup-
pressing nicotine-induced stimulation of mesolimbicDAneurons,
DA release in theNAc, and – in turn –DA-mediated effects of nico-
tine. Accordingly, baclofenmicroinfusion into theVTA suppressed
nicotine self-administration in rats (Corrigall et al., 2000).
In summary, the results of the present study demonstrate
that pretreatment with the orthosteric GABAB receptor agonist,
baclofen, or the GABAB PAMs, CGP7930, and GS39783, sup-
pressed nicotine-induced hyperlocomotion in mice. These data
generalize to nicotine stimulant effects the capacity of baclofen
and GABAB PAMs to suppress several other properties of nicotine
linked to its addictive potential. These data also strengthen the
hypothesis that baclofen and GABAB PAMs may represent poten-
tially useful medications for smoking cessation (see Tyacke et al.,
2010; Vlachou and Markou, 2010).
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